NCT04502706View on ClinicalTrials.gov

Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

PHASE1TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 17, 2020

Primary Completion Date

March 31, 2022

Study Completion Date

March 31, 2022

Conditions
Non-hodgkin Lymphoma
Interventions
DRUG

GS-0189

GS-0189 will be administered intravenously.

DRUG

Rituximab

Rituximab will be administered intravenously.

Trial Locations (5)

34232

Florida Cancer Specialists, Sarasota

35233

University of Alabama Comprehensive Cancer Center, Birmingham

63110

Washington University School of Medicine, St Louis

73104

University of Oklahoma Health Sciences Center, Oklahoma City

91010

City of Hope, Duarte

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT04502706 - Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter